CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00419-07v1
15/2/367    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Scarff, J. M.
Right arrow Articles by Goldberg, J. B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scarff, J. M.
Right arrow Articles by Goldberg, J. B.
Clinical and Vaccine Immunology, February 2008, p. 367-375, Vol. 15, No. 2
1071-412X/08/$08.00+0     doi:10.1128/CVI.00419-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Vaccination against Pseudomonas aeruginosa Pneumonia in Immunocompromised Mice{triangledown}

Jennifer M. Scarff and Joanna B. Goldberg*

Department of Microbiology, University of Virginia Health System, Charlottesville, Virginia

Received 12 October 2007/ Returned for modification 12 November 2007/ Accepted 5 December 2007

Immunocompromised patients are highly susceptible to infection with Pseudomonas aeruginosa. Our laboratory previously showed that intranasal administration of an attenuated Salmonella strain expressing the P. aeruginosa lipopolysaccharide O antigen was effective in clearing bacteria and preventing mortality in wild-type mice after intranasal challenge. We were interested in investigating the efficacy of this vaccine strategy in immunocompromised mice. Mice rendered leukopenic or neutropenic by intraperitoneal treatment with cyclophosphamide (Cy) or RB6-8C5 antibody, respectively, were more susceptible to P. aeruginosa pneumonia than their nontreated counterparts, demonstrating 50% lethal doses several logs lower than that in wild-type mice. This hypersusceptiblity was also associated with bacterial dissemination to the liver and spleen and increased lung permeability in Cy mice. Vaccination of the mice prior to treatment resulted in better survival and lower bacterial loads compared to vector-immunized mice. Although the treatments had no effect on antibody titers, this level of protection was still lower than that seen in untreated vaccinated mice. Administration of antibodies directly to the site of infection at the time of bacterial delivery prolonged survival and lowered bacterial loads in the immunocompromised mice. These results demonstrate the importance of white blood cells while still suggesting a critical role for antibodies in protection against P. aeruginosa infection.


* Corresponding author. Mailing address: 1300 Jefferson Park Ave., 7230 Jordan Hall, Charlottesville, VA 22908-0734. Phone: (434) 243-2774. Fax: (434) 982-1071. E-mail: jbg2b{at}virginia.edu

{triangledown} Published ahead of print on 19 December 2007.


Clinical and Vaccine Immunology, February 2008, p. 367-375, Vol. 15, No. 2
1071-412X/08/$08.00+0     doi:10.1128/CVI.00419-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.